Therapeutic options for mucinous ovarian carcinoma.

doi:10.1016/j.ygyno.2019.12.015

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Therapeutic options for mucinous ovarian carcinoma.

Gynecologic oncology - 1 Mar 2020

Gorringe Kylie L, Cheasley Dane, Wakefield Matthew J, Ryland Georgina L, Allan Prue E, Alsop Kathryn, Amarasinghe Kaushalya C, Ananda Sumitra, Bowtell David D L, Christie Michael, Chiew Yoke-Eng, Churchman Michael, DeFazio Anna, Fereday Sian, Gilks C Blake, Gourley Charlie, Hadley Alison M, Hendley Joy, Hunter Sally M, Kaufmann Scott H, Kennedy Catherine J, Köbel Martin, Le Page Cecile, Li Jason, Lupat Richard, McNally Orla M, McAlpine Jessica N, Pyman Jan, Rowley Simone M, Salazar Carolina, Saunders Hugo, Semple Timothy, Stephens Andrew N, Thio Niko, Torres Michelle C, Traficante Nadia, Zethoven Magnus, Antill Yoland C, Campbell Ian G, Scott Clare L

Abstract excerpt

OBJECTIVE: Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall survival outcomes can occur with early detection and optimal surgical resection, recurrent and advanced disease are associated with extremely poor survival. There are no current guidelines specifically for the systemic management of recurrent MOC. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Homologous Recombination

Share to Immunohistochemistry

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Source

Open in PubMed Open full text

Identifiers

PMID: 31902686
DOI: 10.1016/j.ygyno.2019.12.015
PMCID: PMC7056511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic options for mucinous ovarian carcinoma.PMID 31902686Read ↗

Mismatch Repair Gene Deficiency in Ovarian Cancer: A Clinicopathological Analysis of MLH1, PMS2, MSH2, and MSH6 Mutations Across Histological Subtypes.Semantic proximity Read ↗

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.Semantic proximity Read ↗

Genetic alterations and their therapeutic implications in epithelial ovarian cancer.Semantic proximity Read ↗

Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.Semantic proximity Read ↗

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerSemantic proximity Read ↗

Somatic gene mutations in malignant steroid cell tumours and response to multiple treatments.Semantic proximity Read ↗

Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.Semantic proximity Read ↗

Genetic characteristics of platinum-sensitive ovarian clear cell carcinomaSemantic proximity Read ↗

Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.Semantic proximity Read ↗

Mucinous tumours of the ovary.Semantic proximity Read ↗

The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Semantic proximity Read ↗

Ovarian cancer treatment in mutation carriers/BRCAness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.